Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Delta Air Lines

Marathon Digital Holdings

Stocks are bouncing in the wake of the latest encouraging inflation reading.

3 Stocks Making Outsized Moves Today

Shares of Crispr Therapeutics (NASDAQ: CRSP ) stock are up by about 15% today following continued purchases by Cathie Wood's ARK Invest and an initiation of coverage from Cantor Fitzgerald's Olivia Brayer. Yesterday, Wood purchased a total of 56,492 shares of CRSP stock through the ARK Innovation ETF (NYSEMKT: ARKK ) and the ARK Genomic Revolution ETF (BATS: ARKG ).

Cathie Wood Just Bought More CRISPR Therapeutics (CRSP) Stock

Editas Medicine

Intellia Therapeutics

Against the backdrop of a solid day on Wall Street, CRISPR Therapeutics (NASDAQ: CRSP ) distinguished itself, popping up nearly 16%. The catalyst appears to center on CRISPR's single-dose therapy for sickle cell disease ( SCD ), which it's developing with Vertex Pharmaceuticals (NASDAQ: VRTX ).

Why Are Gene-Editing Stocks CRSP, EDIT, NTLA Stock Up Today?

CRISPR and Vertex Pharmaceuticals are jointly developing a gene-editing therapy to treat sickle cell disease and tranfusion-dependent beta thalassemia. The therapy is in Phase 3 trials and the companies have submitted their biologics license applications to the FDA.

Why Shares of CRISPR Therapeutics Jumped Thursday

Vertex Pharmaceuticals

Vertex Pharmaceuticals has a relatively safe top line, and more growth on the way. CRISPR Therapeutics is on track to start realizing revenue growth like wild.

2 Nasdaq Growth Stocks That Are Screaming Buys in April

Axsome Therapeutics

Axsome launched its first products last year -- and others may be on the horizon. CRISPR recently completed regulatory submissions for a blood disorder candidate with blockbuster potential.

These Up-and-Coming Stocks Are Screaming Buys Right Now

The mean of analysts' price targets for CRISPR Therapeutics AG (CRSP) points to a 105.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Think CRISPR Therapeutics AG (CRSP) Could Surge 105.26%: Read This Before Placing a Bet

ImmunoGen

Vertex Pharmaceuticals recently completed regulatory requests for its blood disorder candidate, exa-cel. Exa-cel has what it takes to become a blockbuster over time.

Could This Move Make Vertex's Next Blockbuster Even Bigger?

CRISPR shares have declined quite a bit from a high a few years ago. But potential good news may be baked into the current price.

CRISPR Stock: Bull vs. Bear

Certara

Incyte

Morphosys AG - ADR

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

bluebird bio

CRISPR Therapeutics and Bluebird Bio will soon likely compete for market share. CRISPR has plenty of money and a collaborator with deep pockets.

What's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio

ARK Innovation ETF

Beam Therapeutics

Coinbase

Ginkgo Bioworks Holdings

Verve Therapeutics

Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.

Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global

CRISPR (CRSP) and Vertex complete BLA submissions to the FDA for exa-cel for treating sickle cell disease and transfusion-dependent beta-thalassemia.

CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced the completion of the rolling Biologics License Applications (BLAs) to the U.S. Food and Drug Administration (FDA) for the investigational treatment exagamglogene autotemcel (exa-cel) for sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals is licensing CRISPR's technology for its type 1 diabetes program. The deal involves an up-front payment, milestone payments -- and the potential for royalties down the road.

Here's a New Million-Dollar Reason to Buy CRISPR Therapeutics

Amazon

Disney

Intuitive Surgical

Tesla

These stocks all have suffered in recent times, but the long-term growth picture remains bright for each one. Buying on the dip and holding for at least five years is a great way to benefit.

5 Bargain-Basement Stocks to Buy Right Now

CTX001 has progressed enough to start discussing details regarding the launch of the program. Regulatory decisions, likely carrying an approval, will likely come in the coming quarters.

Buy Crispr Therapeutics On Approval Odds

Reata Pharmaceuticals

Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzled, it sold off hard as investors sought safer havens.

The 3 Best Growth Stocks to Buy in the Biotech Sector

Legend Biotech

Roivant Sciences Ltd

Ultragenyx Pharmaceutical

While it's a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.

7 Biotech Stocks to Buy for Breakthrough Treatments and Cures

Here is how CRISPR Therapeutics AG (CRSP) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.

Is CRISPR Therapeutics (CRSP) Stock Outpacing Its Medical Peers This Year?

ZUG, Switzerland and BOSTON, March 29, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Brad Bolzon, Ph.D., Chairman and Managing Director of Versant Ventures, is stepping down from the Board of Directors after nearly a decade of service.

CRISPR Therapeutics Announces Departure of Board Member

BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and CRISPR Therapeutics (Nasdaq: CRSP) today announced that they have entered into a new non-exclusive licensing agreement for the use of CRISPR Therapeutics' gene editing technology, known as CRISPR/Cas9, to accelerate the development of Vertex's hypoimmune cell therapies for type 1 diabetes (T1D).

Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 Diabetes

CRISPR has some important elements in common with vaccine giant Moderna. And the company is heading for an important moment in its growth story.

Could CRISPR Therapeutics Become the Next Moderna?

CRISPR's gene editing process could change how we treat disease. The biotech's first potential product, exa-cel, could soon hit the market.

Could This Stock Become the Tesla of Its Industry?

Global X Genomics & Biotechnology ETF

CRISPR could revolutionize the way we treat thousands of diseases. Currently, there are about 7,000 caused by genetic disorders, which occur when a mutation affects your genes, or when you have the wrong amount of genetic material, as noted by the Cleveland Clinic.

News for CRISPR Therapeutics Stock (CRSP)